Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-013565
Filing Date
2022-08-15
Accepted
2022-08-15 08:31:22
Documents
53
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q blph-20220630x10q.htm   iXBRL 10-Q 1057321
2 EX-31.1 blph-20220630xex31d1.htm EX-31.1 9848
3 EX-31.2 blph-20220630xex31d2.htm EX-31.2 9381
4 EX-32 blph-20220630xex32.htm EX-32 9139
  Complete submission text file 0001558370-22-013565.txt   4435005

Data Files

Seq Description Document Type Size
5 EX-101.SCH blph-20220630.xsd EX-101.SCH 34509
6 EX-101.CAL blph-20220630_cal.xml EX-101.CAL 27083
7 EX-101.DEF blph-20220630_def.xml EX-101.DEF 130663
8 EX-101.LAB blph-20220630_lab.xml EX-101.LAB 311031
9 EX-101.PRE blph-20220630_pre.xml EX-101.PRE 241277
47 EXTRACTED XBRL INSTANCE DOCUMENT blph-20220630x10q_htm.xml XML 697825
Mailing Address 184 LIBERTY CORNER ROAD, SUITE 302 WARREN NJ 07059
Business Address 184 LIBERTY CORNER ROAD, SUITE 302 WARREN NJ 07059 908-574-4770
Bellerophon Therapeutics, Inc. (Filer) CIK: 0001600132 (see all company filings)

EIN.: 473116175 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36845 | Film No.: 221162561
SIC: 2834 Pharmaceutical Preparations